# Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2

> **NCT00004883** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 84 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00004883
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-02
- **Primary completion:** 2005-08
- **Final completion:** —
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004883, "Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*